Chronic Laryngitis (Investigational Cervical Adjunct)
Highly investigational cervical adjunct for chronic laryngitis; case reports only; ENT evaluation for underlying causes (LPR, smoking, vocal abuse) remains primary.
Resumen para el Paciente
- ¿Está esto autorizado por FDA para este uso?
- Not FDA-cleared for chronic laryngitis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- ¿Qué evidencia existe?
- Tier C (investigational). No controlled trials. Evidence-based first-line management is identifying and treating the underlying cause: voice rest and speech therapy for voice misuse, proton pump inhibitor therapy and lifestyle changes for reflux laryngitis, smoking cessation, treatment of allergies, and ENT evaluation including stroboscopic laryngoscopy to rule out vocal cord lesions or malignancy.
- Riesgos principales
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- Cervical placement risks (proximity to airway, vessels, recurrent laryngeal nerve)
- Delaying laryngoscopic workup that might detect early laryngeal cancer in a high-risk patient
- Quién no debería considerar esto
- Patients who have not had laryngoscopy with a chronic voice change lasting more than 3-4 weeks
- Smokers or heavy drinkers — laryngeal cancer screening is paramount
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
- People with hemophilia or any other inherited bleeding disorder
- Patients with severe anemia (hemoglobin under 10 g/dL)
- People with an active infection at the planned application site
- Patients who are pregnant or breastfeeding (relative contraindication; insufficient safety data)
- Qué preguntar a su clínico
- Have I had direct laryngoscopy to rule out vocal cord lesions or cancer?
- Have reflux, voice misuse, smoking, and allergy each been addressed?
- What is the published evidence base for leeches in chronic laryngitis?
- How will leech therapy be performed safely in the cervical area?
- How will worsening of an underlying laryngeal lesion be detected during the course?
- What is the success metric — voice quality, endoscopic appearance, both?
- Cuándo buscar atención urgente
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Persistent hoarseness lasting more than 2 weeks (requires urgent ENT laryngoscopy in smokers)
- Coughing up blood, difficulty swallowing solid food, unexplained weight loss, or neck mass
- Stridor or difficulty breathing
Qué NO significa esto
- It does not mean leech therapy is FDA-cleared for laryngitis — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace laryngoscopy and biopsy if cancer is in the differential.
- It does not treat the underlying causes (reflux, voice misuse, smoking, allergies).
- It does not have controlled-trial evidence in this indication.
- It does not heal vocal cord lesions or polyps that require surgical removal.
Referencias cruzadas de seguridad
Clinical Profile
- Category
- ent
- ICD-10
- J37.0, J37.1
- Safety tier
- high
Evidence Summary
Chronic laryngitis management per AAO-HNS includes addressing the underlying etiology (smoking cessation; laryngopharyngeal reflux with PPI and lifestyle modification; voice therapy for vocal abuse; allergy management) and stroboscopic examination to exclude premalignant or vocal-fold lesions. No controlled clinical trial of leech therapy for chronic laryngitis has been published; its use is investigational and mechanistic only, and the diverse etiologies (acid reflux, smoking, vocal abuse) are not addressed by peripheral leech application. Any cervical placement over the anterior neck must avoid the carotid artery and laryngeal cartilage. Evidence is grade D.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Sotnikov OS (2009)0
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Suspected laryngeal malignancy or premalignancy
- Active vocal fold lesion (polyp, nodule, cyst)
- Carotid disease or recent neck surgery
- Smoker not actively engaged in cessation
- Untreated laryngopharyngeal reflux
Related Conditions
Chronic Rhinosinusitis
Off-label use with one RCT showing symptom and SNOT-22 score improvement at 4 weeks in non-polypoid chronic sinusitis.
Subjective Tinnitus
Investigational use for chronic subjective tinnitus; case-series evidence for THI score improvement. Mechanism speculative.
Ménière's Disease (Adjunctive)
Investigational adjunctive use for Ménière's disease; very limited evidence. Standard management (diet, betahistine, intratympanic therapy) remains primary.
Pulsatile Tinnitus (Vascular-Origin Subtype)
Investigational use for pulsatile vascular-origin tinnitus distinct from subjective tinnitus; case-report evidence only.